NasdaqCM - Delayed Quote USD

Exact Sciences Corporation (EXAS)

58.85 +0.06 (+0.10%)
At close: April 26 at 4:00 PM EDT
58.95 +0.10 (+0.17%)
After hours: April 26 at 6:48 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,499,766.00
2,499,766.00
2,084,279.00
1,767,087.00
1,491,391.00
Cost of Revenue
654,200.00
654,200.00
574,400.00
458,757.00
354,300.00
Gross Profit
1,845,566.00
1,845,566.00
1,509,879.00
1,308,330.00
1,137,091.00
Operating Expense
2,059,915.00
2,059,915.00
2,087,412.00
2,143,798.00
1,695,104.00
Operating Income
-214,349.00
-214,349.00
-577,533.00
-835,468.00
-558,013.00
Net Non Operating Interest Income Expense
-29,771.00
-29,771.00
-19,634.00
-18,606.00
-17,122.00
Other Income Expense
42,416.00
42,416.00
-35,394.00
11,568.00
-253,911.00
Pretax Income
-201,746.00
-201,746.00
-632,570.00
-842,506.00
-829,063.00
Tax Provision
2,403.00
2,403.00
-9,064.00
-246,881.00
-5,458.00
Net Income Common Stockholders
-204,149.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Diluted NI Available to Com Stockholders
-204,149.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Basic EPS
-1.58
-1.13
-3.54
-3.48
-5.45
Diluted EPS
-1.58
-1.13
-3.54
-3.48
-5.45
Basic Average Shares
179,262.50
180,144.00
176,351.00
171,348.00
151,137.00
Diluted Average Shares
179,262.50
180,144.00
176,351.00
171,348.00
151,137.00
Total Operating Income as Reported
-215,012.00
-215,012.00
-593,511.00
-855,678.00
-767,696.00
Total Expenses
2,714,115.00
2,714,115.00
2,661,812.00
2,602,555.00
2,049,404.00
Net Income from Continuing & Discontinued Operation
-204,149.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Normalized Income
-237,657.64
-237,657.64
-588,619.16
-603,803.58
-571,217.47
Interest Expense
24,421.00
24,421.00
13,907.00
12,879.00
11,819.00
Net Interest Income
-29,771.00
-29,771.00
-19,634.00
-18,606.00
-17,122.00
EBIT
-177,325.00
-177,325.00
-618,663.00
-829,627.00
-817,244.00
EBITDA
29,283.00
29,283.00
-421,105.00
-649,281.00
-653,882.00
Reconciled Cost of Revenue
539,752.00
539,752.00
474,292.00
373,412.00
284,336.00
Reconciled Depreciation
206,608.00
206,608.00
197,558.00
180,346.00
163,362.00
Net Income from Continuing Operation Net Minority Interest
-204,149.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Total Unusual Items Excluding Goodwill
42,416.00
42,416.00
-35,394.00
11,568.00
-253,911.00
Total Unusual Items
42,416.00
42,416.00
-35,394.00
11,568.00
-253,911.00
Normalized EBITDA
-13,133.00
-13,133.00
-385,711.00
-660,849.00
-399,971.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
8,907.36
8,907.36
-507.16
3,389.42
-1,523.47
12/31/2020 - 2/1/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GH Guardant Health, Inc.
17.35
+1.11%
 
ILMN Illumina, Inc.
122.28
+1.02%
 
TWST Twist Bioscience Corporation
31.54
+1.48%
 
NTRA Natera, Inc.
91.66
+0.42%
 
DHR Danaher Corporation
246.58
+0.32%
 
LH Laboratory Corporation of America Holdings
198.40
+0.03%
 
TMO Thermo Fisher Scientific Inc.
573.60
+0.33%
 
DGX Quest Diagnostics Incorporated
134.26
-0.86%
 
MEDP Medpace Holdings, Inc.
395.93
+1.58%
 
CRL Charles River Laboratories International, Inc.
229.03
+0.54%